Abstract
Background: Data comparing EASL and mRECIST criteria for response evaluation in treatment of hepatocellular carcinoma are rare. We evaluated inter-observer variability by these two response evaluation criteria in treatment-naïve patients undergoing chemoembolization. Methods: For 133 patients undergoing chemoembolization, two radiologists independently measured sum of bi-dimensional and uni-dimensional diameters at baseline using both EASL criteria and mRECIST, and their changes on first follow-up for up to 5 target lesions. Results: Concordance correlation coefficients for sum of bi-dimensional and uni-dimensional diameters at baseline between two observers were 0.992 and 0.988, respectively. However, those for their changes on follow-up were 0.865 and 0.877, respectively. Similarly, mean differences in sum of bi-dimensional and uni-dimensional diameters at baseline between two observers were small; -0.455 and 0.079. cm, respectively. However, mean differences in changes (%) in sum of bi-dimensional and uni-dimensional diameters on first follow-up between observers increased by -9.715% and -9.320%, respectively. Regarding tumour numbers, kappa-value between observers was 0.942. For treatment response (complete or partial response, stable disease and progression), kappa-value was 0.941 by both criteria. When only up to two target lesions were assessed, kappa-value was 1.000 by both criteria. Conclusions: Inter-observer agreements using both response evaluation criteria were excellent, especially when up to two targets were assessed.
| Original language | English |
|---|---|
| Pages (from-to) | 682-688 |
| Number of pages | 7 |
| Journal | Digestive and Liver Disease |
| Volume | 47 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2015 Aug 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Cite this
}
Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. / Kim, Beom Kyung; Kim, Kyung Ah; Kim, Myeong Jin; Park, Junyong; kim, doyoung; Ahn, SangHoon; Han, KwangHyub; Kim, Seungup; Park, Mi Suk.
In: Digestive and Liver Disease, Vol. 47, No. 8, 01.08.2015, p. 682-688.Research output: Contribution to journal › Article
TY - JOUR
T1 - Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization
AU - Kim, Beom Kyung
AU - Kim, Kyung Ah
AU - Kim, Myeong Jin
AU - Park, Junyong
AU - kim, doyoung
AU - Ahn, SangHoon
AU - Han, KwangHyub
AU - Kim, Seungup
AU - Park, Mi Suk
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Background: Data comparing EASL and mRECIST criteria for response evaluation in treatment of hepatocellular carcinoma are rare. We evaluated inter-observer variability by these two response evaluation criteria in treatment-naïve patients undergoing chemoembolization. Methods: For 133 patients undergoing chemoembolization, two radiologists independently measured sum of bi-dimensional and uni-dimensional diameters at baseline using both EASL criteria and mRECIST, and their changes on first follow-up for up to 5 target lesions. Results: Concordance correlation coefficients for sum of bi-dimensional and uni-dimensional diameters at baseline between two observers were 0.992 and 0.988, respectively. However, those for their changes on follow-up were 0.865 and 0.877, respectively. Similarly, mean differences in sum of bi-dimensional and uni-dimensional diameters at baseline between two observers were small; -0.455 and 0.079. cm, respectively. However, mean differences in changes (%) in sum of bi-dimensional and uni-dimensional diameters on first follow-up between observers increased by -9.715% and -9.320%, respectively. Regarding tumour numbers, kappa-value between observers was 0.942. For treatment response (complete or partial response, stable disease and progression), kappa-value was 0.941 by both criteria. When only up to two target lesions were assessed, kappa-value was 1.000 by both criteria. Conclusions: Inter-observer agreements using both response evaluation criteria were excellent, especially when up to two targets were assessed.
AB - Background: Data comparing EASL and mRECIST criteria for response evaluation in treatment of hepatocellular carcinoma are rare. We evaluated inter-observer variability by these two response evaluation criteria in treatment-naïve patients undergoing chemoembolization. Methods: For 133 patients undergoing chemoembolization, two radiologists independently measured sum of bi-dimensional and uni-dimensional diameters at baseline using both EASL criteria and mRECIST, and their changes on first follow-up for up to 5 target lesions. Results: Concordance correlation coefficients for sum of bi-dimensional and uni-dimensional diameters at baseline between two observers were 0.992 and 0.988, respectively. However, those for their changes on follow-up were 0.865 and 0.877, respectively. Similarly, mean differences in sum of bi-dimensional and uni-dimensional diameters at baseline between two observers were small; -0.455 and 0.079. cm, respectively. However, mean differences in changes (%) in sum of bi-dimensional and uni-dimensional diameters on first follow-up between observers increased by -9.715% and -9.320%, respectively. Regarding tumour numbers, kappa-value between observers was 0.942. For treatment response (complete or partial response, stable disease and progression), kappa-value was 0.941 by both criteria. When only up to two target lesions were assessed, kappa-value was 1.000 by both criteria. Conclusions: Inter-observer agreements using both response evaluation criteria were excellent, especially when up to two targets were assessed.
UR - http://www.scopus.com/inward/record.url?scp=84937524598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937524598&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2015.04.004
DO - 10.1016/j.dld.2015.04.004
M3 - Article
C2 - 25977216
AN - SCOPUS:84937524598
VL - 47
SP - 682
EP - 688
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 8
ER -